Polycystic ovary syndrome (PCOS), which is associated with hyperinsulinaemia, hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the adipose tissue, is a heterogeneous reproductive and endocrine disorder.Currently, metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS. SGLT-2 inhibitor, a novel glucose-lowering medication, have been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events in individuals with diabetes mellitus. However, evidences related to its management in non-diabetic PCOS women are limited. Hence, we want to give canangliflozin combined with metformin to women with PCOS to see its effect on insulin resistance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events. Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Body mass index
Changes in body mass index (BMI)
Time frame: Three months
Total testosterone
Changes in total testosterone (TT)
Time frame: Three months
Androstenedione
Changes in androstenedione (AND)
Time frame: Three months
Dehydroepiandrosterone sulfate
Changes in dehydroepiandrosterone sulfate (DHEA-S)
Time frame: Three months
Sex hormone-binding globulin
Changes in sex hormone-binding globulin (SHBG)
Time frame: Three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.